ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) has appointed Timothy P. Clackson, Ph.D., to serve as their first President of Research and Development. Dr. Clackson will assume the position immediately. He will also retain his position as Chief Scientific Officer.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
In this new role, Dr. Clackson will be responsible for establishing an integrated R&D organization for ARIA. He will continue to oversee manufacturing operations and program and alliance management.
ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
